Approval is based on data from the Phase III CodeBreaK 300 trial, which demonstrated that treatment with Lumakras and ...

Approval is based on results from the TROPION-Breast01 Phase III trial, in which Datroway demonstrated a significant reduction in the risk of disease progression or death in patients with previously ...

Panel participants share an optimistic outlook for integrating new innovations, tacking community-level challenges, and more.

The past few years have been a roller coaster ride for M&A in pharma and biotech. After the highs of the pandemic came ...

Ash Shehata from KPMG discusses how investors are feeling about the pharma and life sciences industry heading into 2025.

A new offering in collaboration with Progyny, Inc makes fertility/family-building services more accessible and equitable.

Pharmaceutical companies’ direct-to-patient (DTP) programs have recently sparked conversations and criticism in fear of their potential to “cut out” or influence physicians, the truth is that ...

Cary Claiborne, CEO, Adial Pharmaceuticals, discusses promising results of the AD04-13 study in patients with Alcohol Use Disorder PE: Can you elaborate on the key design elements of the AD04-13 study ...

Organizations including Gilead, Eli Lilly, and AbbVie announced a number of deals addressing inflammatory diseases, multiple myeloma, and other disease areas. With the start of the annual JP Morgan ...

Niktimvo marks the first FDA-approved therapy targeting CSF-1R to address inflammation and fibrosis in chronic graft-versus-host disease. The FDA has approved Incyte’s and Syndax’s Niktimvo ...

Approval was based on results of the VIVID-1 study, which found that Omvoh demonstrated significant clinical remission and endoscopic response rates in patients with Crohn disease. The FDA has ...